Crossject | ALCJ FP | Supergenerics | France | Updates

This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject ^CR	Bloomberg ALCJ FP
Supergenerics / France	Web Site \| Investors Relation

Things are getting going...hopefully

Target

Upside 343%

Price (€) 1.78

Target Price (€) 7.89

Market Cap (€M) 73.2

Perf. 1W:	-6.31%
Perf. 1M:	7.35%
Perf. 3M:	-10.9%
Perf Ytd:	-63.8%

10 day relative perf. to stoxx600:	-4.06%
20 day relative perf. to stoxx600:	9.32%

EPS change05/09/2022 07:56

Download

Adjusting our forecasts to the new number of shares
Change in EPS	2022 : € -0.23 vs -0.26	ns
	2023 : € -0.25 vs -0.31	ns
We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022. As a result, the loss per share for FY22/23 decreases.
Change in NAV	€ 12.3 vs 13.3	-7.88%
We have adjusted our numbers to the current number of shares (after the exercise of subscription rights) which now stands at 34.83m as of August 2022.
Change in DCF	€ 13.3 vs 14.6	-9.05%
We have adjusted our numbers to the current number of shares (after the latest exercise of subscription rights) which now stands at 34.83m as of August 2022.

23 Mar 23 Earnings/sales releases
FY22: not much to learn from the release

12 Jan 23 Financing issue
Crossject has announced it has raised €14m in ...

26 Sep 22 EPS change
Minor changes after H1 22

23 Sep 22 Earnings/sales releases
A rather reassuring H1 22

05 Sep 22 EPS change
Adjusting our forecasts to the new number of sh...

25 Jul 22 EPS change
The update of our assumptions confirms a huge...

22 Jul 22 Latest
The update of our assumptions confirms a huge...

20 Jun 22 Latest
A major breakthrough for Crossject

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing